

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Epidemiological studies from the Atomic Bomb Disease Institute in Japan observed a 17-fold increase in the rate of MDS occurrence among people exposed to the atomic bomb explosions during World War II compared to the general population.
 - True
 - False
- Use of the TGF- β inhibitor luspatercept may result in improvements in which of the following cytopenias observed in MDS?
 - Thrombocytopenia
 - Anemia
 - Neutropenia
 - None of the above
- Which patients with lower-risk MDS who have not yet required blood transfusions are more likely to respond to erythropoiesis-stimulating agents?
 - Those with higher erythropoietin levels
 - Those with lower erythropoietin levels
 - Neither a nor b
- What is the response rate with hypomethylating agents for patients with lower-risk MDS?
 - Less than 10%
 - Between 30% and 40%
 - Higher than 60%
- Approximately what proportion of patients with lower-risk del(5q) MDS who are blood transfusion dependent can achieve transfusion independence with lenalidomide treatment?
 - Less than 20%
 - 40%
 - 60%
- Approximately 25% of patients with lower-risk MDS without del(5q) respond to treatment with lenalidomide.
 - True
 - False
- The rate of cure for patients with MDS undergoing transplantation is approximately 30% to 40%, whereas the mortality rate associated with transplantation is 1% to 3%.
 - True
 - False
- The IPSS-R prognostic scoring system comprises which of the following risk categories for patients with MDS?
 - High, intermediate and low
 - Very high, high, intermediate, low and very low
 - Neither a nor b
- For patients with lower-risk MDS and del(5q) who experience disease progression while receiving lenalidomide therapy, the response rate to subsequent treatment with a hypomethylating agent is _____.
 - Similar to the response rate for patients with higher-risk MDS initiating treatment with a hypomethylating agent
 - Lower than the response rate for patients with higher-risk MDS initiating treatment with a hypomethylating agent
 - Neither a nor b: The response rate in this setting is unknown and subject to evaluation in clinical trials
- Which patients with MDS and otherwise similar prognostic indicators are likely to have better treatment outcomes?
 - Patients with a secondary, therapy-related myeloid neoplasm
 - Patients with a primary, de novo myeloid neoplasm
 - Neither a nor b